SG11202106398WA - Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy - Google Patents
Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapyInfo
- Publication number
- SG11202106398WA SG11202106398WA SG11202106398WA SG11202106398WA SG11202106398WA SG 11202106398W A SG11202106398W A SG 11202106398WA SG 11202106398W A SG11202106398W A SG 11202106398WA SG 11202106398W A SG11202106398W A SG 11202106398WA SG 11202106398W A SG11202106398W A SG 11202106398WA
- Authority
- SG
- Singapore
- Prior art keywords
- prognosis
- methods
- breast cancer
- adjuvant radiotherapy
- predicting benefit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Evolutionary Biology (AREA)
- Biochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Artificial Intelligence (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Databases & Information Systems (AREA)
- Cell Biology (AREA)
- Computer Vision & Pattern Recognition (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862755546P | 2018-11-04 | 2018-11-04 | |
PCT/IB2019/001181 WO2020089691A1 (en) | 2018-11-04 | 2019-11-04 | Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106398WA true SG11202106398WA (en) | 2021-07-29 |
Family
ID=70463506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106398WA SG11202106398WA (en) | 2018-11-04 | 2019-11-04 | Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220002815A1 (en) |
EP (1) | EP3874062A4 (en) |
CN (2) | CN113748215B (en) |
AU (1) | AU2019370860A1 (en) |
CA (1) | CA3118585A1 (en) |
SG (1) | SG11202106398WA (en) |
WO (1) | WO2020089691A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009102788A2 (en) | 2008-02-15 | 2009-08-20 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
EP3126529B1 (en) | 2014-03-31 | 2020-05-27 | Mayo Foundation for Medical Education and Research | Detecting colorectal neoplasm |
AU2021272986A1 (en) * | 2020-05-13 | 2022-12-22 | Prelude Corporation | PD-1 as a predictive marker for therapy in cancer |
IL305500A (en) * | 2021-03-01 | 2023-10-01 | Pfs Genomics Inc | Methods and genomic classifiers for prognosis of breast cancer and identifying subjects not likely to benefit from radiotherapy |
CN115612743B (en) * | 2022-12-14 | 2023-03-21 | 中国医学科学院北京协和医院 | HPV integration gene combination and application thereof in prediction of cervical cancer recurrence and metastasis |
CN117965734B (en) * | 2024-02-02 | 2024-09-24 | 奥明星程(杭州)生物科技有限公司 | Gene marker for detecting hard fibroid, kit, detection method and application |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1852974A (en) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | Compositions and methods for treating and diagnosing cancer |
CN1898563B (en) * | 2003-09-24 | 2011-11-23 | 肿瘤疗法科学股份有限公司 | Method of diagnosing breast cancer |
EP1960551A2 (en) * | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
EP2080140B1 (en) * | 2006-11-03 | 2013-04-24 | Baylor Research Institute | Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis |
WO2009158143A1 (en) * | 2008-05-30 | 2009-12-30 | The University Of North Carolina At Chapel Hill | Gene expression profiles to predict breast cancer outcomes |
SG10202010758SA (en) * | 2011-11-08 | 2020-11-27 | Genomic Health Inc | Method of predicting breast cancer prognosis |
EP3047037B1 (en) * | 2013-09-20 | 2019-11-27 | The Regents Of The University Of Michigan | Method for the analysis of radiosensitivity |
WO2016004387A1 (en) * | 2014-07-02 | 2016-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gene expression signature for cancer prognosis |
TWI582240B (en) * | 2015-05-19 | 2017-05-11 | 鄭鴻鈞 | Prediction of local and regional recurrence and response to radiotherapy in breast cancer by genomic prognostic kits |
GB201609977D0 (en) * | 2016-06-08 | 2016-07-20 | Cancer Rec Tech Ltd | Chemosensitivity predictive biomarkers |
-
2019
- 2019-11-04 US US17/290,759 patent/US20220002815A1/en active Pending
- 2019-11-04 CA CA3118585A patent/CA3118585A1/en active Pending
- 2019-11-04 AU AU2019370860A patent/AU2019370860A1/en active Pending
- 2019-11-04 CN CN201980087717.5A patent/CN113748215B/en active Active
- 2019-11-04 WO PCT/IB2019/001181 patent/WO2020089691A1/en unknown
- 2019-11-04 SG SG11202106398WA patent/SG11202106398WA/en unknown
- 2019-11-04 EP EP19880585.5A patent/EP3874062A4/en active Pending
- 2019-11-04 CN CN202410949195.8A patent/CN118685516A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220002815A1 (en) | 2022-01-06 |
CA3118585A1 (en) | 2020-05-07 |
WO2020089691A1 (en) | 2020-05-07 |
CN113748215A (en) | 2021-12-03 |
EP3874062A1 (en) | 2021-09-08 |
AU2019370860A1 (en) | 2021-06-24 |
EP3874062A4 (en) | 2022-08-24 |
CN118685516A (en) | 2024-09-24 |
CN113748215B (en) | 2024-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202106398WA (en) | Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy | |
EP3524689C0 (en) | Method for predicting the prognosis of breast cancer patient | |
SG11201907102XA (en) | Immunological biomarker for predicting clinical effect of cancer immunotherapy | |
IL280760A (en) | Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type | |
IL283780A (en) | Transcriptomic profiling for prognosis of breast cancer | |
IL289297A (en) | Adjuvant treatment of her2-positive breast cancer | |
IL276167A (en) | Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof | |
IL268235A (en) | Improved methods for assessing risk of developing breast cancer | |
IL288970A (en) | Methods of detecting and predicting breast cancer | |
EP3524690C0 (en) | Method for predicting effectiveness of chemotherapy in breast cancer patients | |
IL273844A (en) | Methods of assessing risk of developing breast cancer | |
SG11202109835WA (en) | Methods for predicting prostate cancer and uses thereof | |
GB201619808D0 (en) | Biomarkers for the prognosis and diagnosis of cancer | |
EP3880846C0 (en) | Gene signatures for the prediction of prostate cancer recurrence | |
GB202113759D0 (en) | Methods of cancer prognosis | |
GB201617722D0 (en) | Method for determining prognosis of cancer | |
SG11202011007UA (en) | Methods for early prediction, treatment response, recurrence and prognosis monitoring of breast cancer | |
IL265238A (en) | Methods of prognosing breast cancer and treating same | |
IL269295A (en) | Methods of treating breast cancer | |
GB202116412D0 (en) | Methods for detecting and predicting breast cancer | |
GB202009217D0 (en) | Methods for detecting and predicting breast cancer | |
IL288421A (en) | Breast cancer detection methods | |
AU2017900208A0 (en) | Improved methods for assessing risk of developing breast cancer | |
AU2017904153A0 (en) | Methods of assessing risk of developing breast cancer | |
GB201808839D0 (en) | Method of predicting survival rates for cancer patients |